Open AccessCardiovascular effects of the incretin‐based therapy: the good, the bad, or the ugly?
Author(s) -
Cho Young Min
Publication year - 2015
Publication title -
journal of diabetes investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.089
H-Index - 50
eISSN - 2040-1124
pISSN - 2040-1116
DOI - 10.1111/jdi.12386
Subject(s) - incretin , medicine , type 2 diabetes , diabetes mellitus , endocrinology , exenatide , glucagon like peptide 1 , hormone , gastric inhibitory polypeptide , glucagon , pharmacology
Type 2 diabetes increases the risk of cardiovascular events. Incretin‐based therapy does not increase the risk of cardiovascular events in general. However, the risk of hospital admission for heart failure in people using dipeptidyl peptidase‐4 inhibitors is inconsistent, which requires more attention and further research.